These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

189 related items for PubMed ID: 21635257

  • 1. Metronidazole leads to enhanced uptake of imatinib in brain, liver and kidney without affecting its plasma pharmacokinetics in mice.
    Tan SY, Kan E, Lim WY, Chay G, Law JH, Soo GW, Bukhari NI, Segarra I.
    J Pharm Pharmacol; 2011 Jul; 63(7):918-25. PubMed ID: 21635257
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Disposition and tissue distribution of imatinib in a liposome formulation after intravenous bolus dose to mice.
    Moo KS, Radhakrishnan S, Teoh M, Narayanan P, Bukhari NI, Segarra I.
    Yao Xue Xue Bao; 2010 Jul; 45(7):901-8. PubMed ID: 20931790
    [Abstract] [Full Text] [Related]

  • 4. Pharmacokinetic interaction between ketoconazole and imatinib mesylate (Glivec) in healthy subjects.
    Dutreix C, Peng B, Mehring G, Hayes M, Capdeville R, Pokorny R, Seiberling M.
    Cancer Chemother Pharmacol; 2004 Oct; 54(4):290-4. PubMed ID: 15138710
    [Abstract] [Full Text] [Related]

  • 5. Effect of rifampicin on the pharmacokinetics of imatinib mesylate (Gleevec, STI571) in healthy subjects.
    Bolton AE, Peng B, Hubert M, Krebs-Brown A, Capdeville R, Keller U, Seiberling M.
    Cancer Chemother Pharmacol; 2004 Feb; 53(2):102-6. PubMed ID: 14605865
    [Abstract] [Full Text] [Related]

  • 6. The influence of St. John's wort on the pharmacokinetics and protein binding of imatinib mesylate.
    Smith P, Bullock JM, Booker BM, Haas CE, Berenson CS, Jusko WJ.
    Pharmacotherapy; 2004 Nov; 24(11):1508-14. PubMed ID: 15537555
    [Abstract] [Full Text] [Related]

  • 7. HPLC determination of imatinib in plasma and tissues after multiple oral dose administration to mice.
    Teoh M, Narayanan P, Moo KS, Radhakrisman S, Pillappan R, Bukhari NI, Segarra I.
    Pak J Pharm Sci; 2010 Jan; 23(1):35-41. PubMed ID: 20067864
    [Abstract] [Full Text] [Related]

  • 8. Imatinib disposition and ABCB1 (MDR1, P-glycoprotein) genotype.
    Gurney H, Wong M, Balleine RL, Rivory LP, McLachlan AJ, Hoskins JM, Wilcken N, Clarke CL, Mann GJ, Collins M, Delforce SE, Lynch K, Schran H.
    Clin Pharmacol Ther; 2007 Jul; 82(1):33-40. PubMed ID: 17495881
    [Abstract] [Full Text] [Related]

  • 9. Effect of St John's wort on imatinib mesylate pharmacokinetics.
    Frye RF, Fitzgerald SM, Lagattuta TF, Hruska MW, Egorin MJ.
    Clin Pharmacol Ther; 2004 Oct; 76(4):323-9. PubMed ID: 15470331
    [Abstract] [Full Text] [Related]

  • 10. Sunitinib tissue distribution changes after coadministration with ketoconazole in mice.
    Chee EL, Lim AY, Modamio P, Fernandez-Lastra C, Segarra I.
    Eur J Drug Metab Pharmacokinet; 2016 Jun; 41(3):309-19. PubMed ID: 25656737
    [Abstract] [Full Text] [Related]

  • 11. Metabolism and disposition of imatinib mesylate in healthy volunteers.
    Gschwind HP, Pfaar U, Waldmeier F, Zollinger M, Sayer C, Zbinden P, Hayes M, Pokorny R, Seiberling M, Ben-Am M, Peng B, Gross G.
    Drug Metab Dispos; 2005 Oct; 33(10):1503-12. PubMed ID: 16006570
    [Abstract] [Full Text] [Related]

  • 12. Pharmacokinetic-pharmacodynamic relationships of imatinib and its main metabolite in patients with advanced gastrointestinal stromal tumors.
    Delbaldo C, Chatelut E, Ré M, Deroussent A, Séronie-Vivien S, Jambu A, Berthaud P, Le Cesne A, Blay JY, Vassal G.
    Clin Cancer Res; 2006 Oct 15; 12(20 Pt 1):6073-8. PubMed ID: 17062683
    [Abstract] [Full Text] [Related]

  • 13. Alpha1 acid glycoprotein binds to imatinib (STI571) and substantially alters its pharmacokinetics in chronic myeloid leukemia patients.
    Gambacorti-Passerini C, Zucchetti M, Russo D, Frapolli R, Verga M, Bungaro S, Tornaghi L, Rossi F, Pioltelli P, Pogliani E, Alberti D, Corneo G, D'Incalci M.
    Clin Cancer Res; 2003 Feb 15; 9(2):625-32. PubMed ID: 12576428
    [Abstract] [Full Text] [Related]

  • 14. Pharmacokinetics of imatinib mesylate in end stage renal disease. A case study.
    Pappas P, Karavasilis V, Briasoulis E, Pavlidis N, Marselos M.
    Cancer Chemother Pharmacol; 2005 Oct 15; 56(4):358-60. PubMed ID: 15883819
    [Abstract] [Full Text] [Related]

  • 15. Absolute bioavailability of imatinib (Glivec) orally versus intravenous infusion.
    Peng B, Dutreix C, Mehring G, Hayes MJ, Ben-Am M, Seiberling M, Pokorny R, Capdeville R, Lloyd P.
    J Clin Pharmacol; 2004 Feb 15; 44(2):158-62. PubMed ID: 14747424
    [Abstract] [Full Text] [Related]

  • 16. Population pharmacokinetics of imatinib in Iranian patients with chronic-phase chronic myeloid leukemia.
    Golabchifar AA, Rezaee S, Ghavamzadeh A, Alimoghaddam K, Dinan NM, Rouini MR.
    Cancer Chemother Pharmacol; 2014 Jul 15; 74(1):85-93. PubMed ID: 24817601
    [Abstract] [Full Text] [Related]

  • 17. Population pharmacokinetics of imatinib mesylate and its metabolite in children and young adults.
    Menon-Andersen D, Mondick JT, Jayaraman B, Thompson PA, Blaney SM, Bernstein M, Bond M, Champagne M, Fossler MJ, Barrett JS.
    Cancer Chemother Pharmacol; 2009 Jan 15; 63(2):229-38. PubMed ID: 18398615
    [Abstract] [Full Text] [Related]

  • 18. Sunitinib-ibuprofen drug interaction affects the pharmacokinetics and tissue distribution of sunitinib to brain, liver, and kidney in male and female mice differently.
    Lau CL, Chan ST, Selvaratanam M, Khoo HW, Lim AY, Modamio P, Mariño EL, Segarra I.
    Fundam Clin Pharmacol; 2015 Aug 15; 29(4):404-16. PubMed ID: 26011058
    [Abstract] [Full Text] [Related]

  • 19. Effect of cigarette smoking on imatinib in patients in the soft tissue and bone sarcoma group of the EORTC.
    van Erp N, Gelderblom H, van Glabbeke M, Van Oosterom A, Verweij J, Guchelaar HJ, Debiec-Rychter M, Peng B, Blay JY, Judson I.
    Clin Cancer Res; 2008 Dec 15; 14(24):8308-13. PubMed ID: 19088049
    [Abstract] [Full Text] [Related]

  • 20. Bioequivalence of two film-coated tablets of imatinib mesylate 400 mg: a randomized, open-label, single-dose, fasting, two-period, two-sequence crossover comparison in healthy male South American volunteers.
    Parrillo-Campiglia S, Ercoli MC, Umpierrez O, Rodríguez P, Márquez S, Guarneri C, Estevez-Parrillo FT, Laurenz M, Estevez-Carrizo FE.
    Clin Ther; 2009 Oct 15; 31(10):2224-32. PubMed ID: 19922893
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.